Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32685322 | 1.00 | CNR1 (0.45) | CNR1GAAHTR1AEPHX2LMNA | |
| SCHEMBL30352810 | 0.90 | CNR1 (0.44) | CNR1GAAHTR1AEPHX2 | |
| SCHEMBL30352895 | 0.90 | CNR1 (0.43) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL21752465 | 0.90 | CNR1 (0.43) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL21752505 | 0.88 | CNR1 (0.47) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL30352819 | 0.88 | CNR1 (0.47) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL21752673 | 0.84 | IDO1 (0.47) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL32685324 | 0.84 | IDO1 (0.47) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL21752667 | 0.84 | IDO1 (0.47) | CNR1GAAEPHX2LMNATP53 | |
| SCHEMBL30352855 | 0.84 | IDO1 (0.47) | CNR1GAAEPHX2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | claimed |
| EP-3840747-B1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | claimed |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | claimed |
| EP-3840747-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-30 | — | — | EP | claimed |
| WO-2020041100-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | WO | claimed |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | CNR1 139/4885GAA 1470/4885HTR1A 100/4885 |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, KYNU | CNR1 1075/4885GAA 202/4885HTR1A 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.